Next-gen platforms poised to redefine crowded hereditary angioedema landscape

The hereditary angioedema (HAE) pharmaceutical landscape is evolving at an unprecedented speed. Following a surge of approvals in recent years, the market is now facing a late-stage development bottleneck, as 46% of pipeline drugs are currently in Phase III.

This concentration of late-stage assets suggests a wave of approvals in the coming years, potentially creating a crowded rare disease market. Emerging technologies such as clustered regularly interspaced short palindromic repeats (CRISPR) and small interfering RNA (siRNA) platforms may provide meaningful differentiation in an otherwise competitive landscape, according to pharma intelligence firm GlobalData.